Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: A case report

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1627-1630

  Bjelic Radisic, Vesna ^a   Stoger H ^a   Winter, R ^a   Beham Schmid, C ^a   Petru, E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antihormonal therapy; Bone marrow carcinosis; Metastatic breast cancer; Thrombocytopenia; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PAMIDRONIC ACID; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; TUMOR MARKER;

ADULT; ANEMIA; ARTICLE; BLOOD EXAMINATION; BONE MARROW BIOPSY; BONE MARROW CANCER; BONE METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMATOSIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; ERYTHROPOIESIS; FEBRILE NEUTROPENIA; HUMAN; HUMAN TISSUE; LEUKOPENIA; LEUKOPOIESIS; LUNG METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; THROMBOCYTOPENIA;

EID: 33645832011     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bonneterre B, Thürlimann J, Robertson FR, Krzakowski M, Mauriac L, Koralewski P et al: Anastrosole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 18: 3748-3757, 2000.
2. Dieing A, Georgieva G, Schmied P, Regierer AC, Ehlers N, Flath B and Possinger K: Benefit of cytostatic therapy in 3rd and following line in metastatic breast cancer. ASCO Annual Meeting: Abstr 742, 2005.
3. Ballot J, McDonnell D and Crown J: Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel. J Natl Cancer Inst 95: 831-832, 2003.
4. Dady PJ, Gazet JC, Ford HT and Powles TJ: Combination chemotherapy for thrombocytopenia with bone marrow metastases from breast cancer. Br Med J 26: 554, 1977.
5. Sugarbaker PH, Skarin AT and Wilson RE: Thrombocytopenia from metastatic cacrcinoma of the breast. Arch Surg 107: 523-527, 1973.
6. Rodriguez-Kraul R, Hortobagyi GN, Buzdar AU and Blumenschein GR: Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer 48: 227-232, 1981.
7. Elting SL, Rubenstein EB, Martin ChG, Kurtin D, Rodriguez S, Laiho E et al: Incidence, cost and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19: 1137-1146, 2001.
8. Wong ZW, Isaacs C, Harris L and Ellis MJ: A phase II trial af letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Breast Cancer Res Treat 82: 106, Abstr 444, 2003.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 344: 783-792, 2001.
10. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM et al: Clinical activity of trastuzumab and vinorelbine with Her-2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-2730, 2001.
11. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E et al: Comparison of fulvestrant versus tamoxifen treatment of advanced breast cancer in postmenopausal women previously under endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605-1613, 2004.